The company said revenue for Q4 2023 rose to $2.1 billion, up 41% on a reported basis and 9% on an organic basis. Earnings per share for Q4 were $1.10, up 34%, and $0.99 on an adjusted basis, down 1%.

1. 01

   The company said revenue for Q4 2023 rose to $2.1 billion, up 41% on a reported basis and 9% on an organic basis. Earnings per share for Q4 were $1.10, up 34%, and $0.99 on an adjusted basis, down 1%.

2. 02

   The company said net income for Q4 was $266 million, and net income margin was 12.6%, up 270 basis points. It cited non-recurring tax benefits as one of the factors. Adjusted EBITDA margin for Q4 was 19.6%, up 90 basis points from a year earlier.

3. 03

   Xylem said full-year revenue for 2023 was $7.4 billion, up 33% on a reported basis and 12% on an organic basis. Full-year earnings per share were $2.79, up 42%; on an adjusted basis, they were $3.78, up 20%.

4. 04

   Xylem said it expects full-year 2024 revenue of $8.4 billion to $8.5 billion and adjusted earnings per share of $4.00 to $4.20. The company also said its board declared a dividend of $0.36 per share for Q1, an increase of 9%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.